Which has better valuation and earnings, HSCS or MBAI?

HeartSciences is trading at a lower price-to-earnings ratio than MBody AI, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HeartSciences N/A N/A -$9.14M -$3.22 N/A MBody AI N/A N/A $4.14M -$7.42 N/A

Is HSCS or MBAI more profitable?

MBody AI's return on equity of 0.00% beat HeartSciences' return on equity. Company Net Margins Return on Equity Return on Assets HeartSciences N/A -816.90% -181.97% MBody AI N/A N/A N/A

Does the media refer more to HSCS or MBAI?

In the previous week, MBody AI had 1 more articles in the media than HeartSciences. MarketBeat recorded 3 mentions for MBody AI and 2 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.73 beat MBody AI's score of 0.61 indicating that HeartSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBody AI 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FEMY or MBAI more profitable?

MBody AI has a net margin of 0.00% compared to Femasys' net margin of -534.36%. MBody AI's return on equity of 0.00% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% MBody AI N/A N/A N/A

Does the media prefer FEMY or MBAI?

In the previous week, Femasys had 1 more articles in the media than MBody AI. MarketBeat recorded 4 mentions for Femasys and 3 mentions for MBody AI. MBody AI's average media sentiment score of 0.61 beat Femasys' score of 0.45 indicating that MBody AI is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBody AI 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MBAI or ICU?

In the previous week, SeaStar Medical had 3 more articles in the media than MBody AI. MarketBeat recorded 6 mentions for SeaStar Medical and 3 mentions for MBody AI. SeaStar Medical's average media sentiment score of 0.63 beat MBody AI's score of 0.61 indicating that SeaStar Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBody AI 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SeaStar Medical 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IRIX or MBAI more profitable?

MBody AI has a net margin of 0.00% compared to IRIDEX's net margin of -6.88%. Company Net Margins Return on Equity Return on Assets IRIDEX -6.88% N/A -12.55% MBody AI N/A N/A N/A

Does the media refer more to IRIX or MBAI?

In the previous week, IRIDEX had 132 more articles in the media than MBody AI. MarketBeat recorded 135 mentions for IRIDEX and 3 mentions for MBody AI. IRIDEX's average media sentiment score of 0.85 beat MBody AI's score of 0.61 indicating that IRIDEX is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IRIDEX 2 Very Positive mention(s) 22 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MBody AI 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MBAI or CTSO more profitable?

MBody AI has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. MBody AI's return on equity of 0.00% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets MBody AI N/A N/A N/A Cytosorbents -48.94% -431.65% -41.94%

Does the media prefer MBAI or CTSO?

In the previous week, MBody AI and MBody AI both had 3 articles in the media. MBody AI's average media sentiment score of 0.61 equaled Cytosorbents'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBody AI 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MBody AI (MBAI) Competitors

$3.06 -0.02 (-0.49%)

As of 10:17 AM Eastern

Compare

MBAI vs. HSCS, FEMY, ICU, IRIX, and CTSO

Should you buy MBody AI stock or one of its competitors? MBody AI's main competitors and comparable companies include HeartSciences (HSCS), Femasys (FEMY), SeaStar Medical (ICU), IRIDEX (IRIX), and Cytosorbents (CTSO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does MBody AI compare to HeartSciences?

HeartSciences (NASDAQ:HSCS) and MBody AI (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

HeartSciences is trading at a lower price-to-earnings ratio than MBody AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A
MBody AI	N/A	N/A	$4.14M	-$7.42	N/A

17.2% of HeartSciences shares are held by institutional investors. Comparatively, 1.1% of MBody AI shares are held by institutional investors. 4.9% of HeartSciences shares are held by company insiders. Comparatively, 0.5% of MBody AI shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MBody AI's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartSciences	N/A	-816.90%	-181.97%
MBody AI	N/A	N/A	N/A

HeartSciences currently has a consensus price target of $8.00, suggesting a potential upside of 158.90%. MBody AI has a consensus price target of $10.00, suggesting a potential upside of 225.73%. Given MBody AI's higher probable upside, analysts clearly believe MBody AI is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MBody AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, MBody AI has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

In the previous week, MBody AI had 1 more articles in the media than HeartSciences. MarketBeat recorded 3 mentions for MBody AI and 2 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.73 beat MBody AI's score of 0.61 indicating that HeartSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MBody AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

HeartSciences and MBody AI tied by winning 5 of the 10 factors compared between the two stocks.

How does MBody AI compare to Femasys?

Femasys (NASDAQ:FEMY) and MBody AI (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Femasys has a beta of -2.16, suggesting that its stock price is 316% less volatile than the broader market. Comparatively, MBody AI has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

MBody AI has lower revenue, but higher earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than MBody AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	6.44	-$18.63M	-$3.53	N/A
MBody AI	N/A	N/A	$4.14M	-$7.42	N/A

65.3% of Femasys shares are held by institutional investors. Comparatively, 1.1% of MBody AI shares are held by institutional investors. 7.8% of Femasys shares are held by insiders. Comparatively, 0.5% of MBody AI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Femasys had 1 more articles in the media than MBody AI. MarketBeat recorded 4 mentions for Femasys and 3 mentions for MBody AI. MBody AI's average media sentiment score of 0.61 beat Femasys' score of 0.45 indicating that MBody AI is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBody AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Femasys presently has a consensus target price of $50.00, suggesting a potential upside of 2,740.91%. MBody AI has a consensus target price of $10.00, suggesting a potential upside of 225.73%. Given Femasys' stronger consensus rating and higher probable upside, equities research analysts clearly believe Femasys is more favorable than MBody AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
MBody AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MBody AI has a net margin of 0.00% compared to Femasys' net margin of -534.36%. MBody AI's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
MBody AI	N/A	N/A	N/A

Summary

Femasys beats MBody AI on 8 of the 14 factors compared between the two stocks.

How does MBody AI compare to SeaStar Medical?

MBody AI (NASDAQ:MBAI) and SeaStar Medical (NASDAQ:ICU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

MBody AI has higher earnings, but lower revenue than SeaStar Medical. SeaStar Medical is trading at a lower price-to-earnings ratio than MBody AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBody AI	N/A	N/A	$4.14M	-$7.42	N/A
SeaStar Medical	$1.23M	12.87	-$12.15M	-$3.91	N/A

MBody AI has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.09, indicating that its share price is 209% less volatile than the broader market.

MBody AI has a net margin of 0.00% compared to SeaStar Medical's net margin of -795.51%. MBody AI's return on equity of 0.00% beat SeaStar Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBody AI	N/A	N/A	N/A
SeaStar Medical	-795.51%	-162.75%	-109.89%

1.1% of MBody AI shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 0.5% of MBody AI shares are held by insiders. Comparatively, 0.7% of SeaStar Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, SeaStar Medical had 3 more articles in the media than MBody AI. MarketBeat recorded 6 mentions for SeaStar Medical and 3 mentions for MBody AI. SeaStar Medical's average media sentiment score of 0.63 beat MBody AI's score of 0.61 indicating that SeaStar Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBody AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SeaStar Medical	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBody AI presently has a consensus price target of $10.00, indicating a potential upside of 225.73%. SeaStar Medical has a consensus price target of $8.00, indicating a potential upside of 122.84%. Given MBody AI's higher possible upside, equities analysts plainly believe MBody AI is more favorable than SeaStar Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBody AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MBody AI and SeaStar Medical tied by winning 6 of the 12 factors compared between the two stocks.

How does MBody AI compare to IRIDEX?

IRIDEX (NASDAQ:IRIX) and MBody AI (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

20.1% of IRIDEX shares are held by institutional investors. Comparatively, 1.1% of MBody AI shares are held by institutional investors. 8.6% of IRIDEX shares are held by company insiders. Comparatively, 0.5% of MBody AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, IRIDEX had 132 more articles in the media than MBody AI. MarketBeat recorded 135 mentions for IRIDEX and 3 mentions for MBody AI. IRIDEX's average media sentiment score of 0.85 beat MBody AI's score of 0.61 indicating that IRIDEX is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IRIDEX	2 Very Positive mention(s)	22 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MBody AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IRIDEX currently has a consensus price target of $3.00, indicating a potential upside of 253.65%. MBody AI has a consensus price target of $10.00, indicating a potential upside of 225.73%. Given IRIDEX's higher possible upside, research analysts plainly believe IRIDEX is more favorable than MBody AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MBody AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MBody AI has lower revenue, but higher earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than MBody AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67M	0.28	-$4.44M	-$0.20	N/A
MBody AI	N/A	N/A	$4.14M	-$7.42	N/A

MBody AI has a net margin of 0.00% compared to IRIDEX's net margin of -6.88%.

Company	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.88%	N/A	-12.55%
MBody AI	N/A	N/A	N/A

IRIDEX has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, MBody AI has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Summary

IRIDEX beats MBody AI on 8 of the 11 factors compared between the two stocks.

How does MBody AI compare to Cytosorbents?

MBody AI (NASDAQ:MBAI) and Cytosorbents (NASDAQ:CTSO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

1.1% of MBody AI shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 0.5% of MBody AI shares are held by company insiders. Comparatively, 7.8% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MBody AI presently has a consensus target price of $10.00, indicating a potential upside of 225.73%. Cytosorbents has a consensus target price of $107.50, indicating a potential upside of 3,006.94%. Given Cytosorbents' higher possible upside, analysts clearly believe Cytosorbents is more favorable than MBody AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBody AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MBody AI has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. MBody AI's return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBody AI	N/A	N/A	N/A
Cytosorbents	-48.94%	-431.65%	-41.94%

MBody AI has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

In the previous week, MBody AI and MBody AI both had 3 articles in the media. MBody AI's average media sentiment score of 0.61 equaled Cytosorbents'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBody AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBody AI has higher earnings, but lower revenue than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than MBody AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBody AI	N/A	N/A	$4.14M	-$7.42	N/A
Cytosorbents	$37.06M	0.29	-$8.20M	-$5.80	N/A

Summary

Cytosorbents beats MBody AI on 6 of the 10 factors compared between the two stocks.

Get MBody AI News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBAI vs. The Competition

Export

Metric	MBody AI	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.22M	$5.55B	$7.26B	$13.10B
Dividend Yield	N/A	1.75%	2.52%	22.89%
P/E Ratio	-0.41	25.60	275.54	25.58
Price / Sales	N/A	67.27	557.67	80.26
Price / Cash	0.85	32.25	77.16	53.04
Price / Book	0.93	5.82	10.81	6.02
Net Income	$4.14M	$146.14M	$3.49B	$380.34M
7 Day Performance	-4.83%	-1.38%	-3.00%	-3.19%
1 Month Performance	-51.51%	-4.06%	-7.48%	-6.07%
1 Year Performance	N/A	0.95%	3.18%	-3.77%

MBody AI Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBAI MBody AI	2.8766 of 5 stars	$3.06 -0.5%	$10.00 +227.3%	N/A	$4.22M	N/A	N/A	85	Positive News
HSCS HeartSciences	2.8332 of 5 stars	$3.49 -7.4%	$8.00 +129.2%	-13.7%	$16.91M	$4.52K	N/A	14
FEMY Femasys	3.8236 of 5 stars	$2.00 -3.8%	$50.00 +2,400.0%	-83.5%	$16.75M	$2.30M	N/A	54	News Coverage
ICU SeaStar Medical	2.9758 of 5 stars	$3.72 +16.6%	$8.00 +115.1%	-34.1%	$16.39M	$1.71M	N/A	2	High Trading Volume
IRIX IRIDEX	2.9079 of 5 stars	$0.88 +29.4%	$3.00 +240.9%	-18.8%	$15.46M	$51.57M	N/A	108	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBAI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MBody AI (MBAI) Competitors

MBAI vs. HSCS, FEMY, ICU, IRIX, and CTSO

How does MBody AI compare to HeartSciences?

Summary

How does MBody AI compare to Femasys?

Summary

How does MBody AI compare to SeaStar Medical?

Summary

How does MBody AI compare to IRIDEX?

Summary

How does MBody AI compare to Cytosorbents?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBAI vs. The Competition

MBody AI Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MBody AI (MBAI) Competitors

MBAI vs. HSCS, FEMY, ICU, IRIX, and CTSO

How does MBody AI compare to HeartSciences?

Which has better valuation and earnings, HSCS or MBAI?

Do institutionals & insiders hold more shares of HSCS or MBAI?

Is HSCS or MBAI more profitable?

Do analysts recommend HSCS or MBAI?

Which has more risk & volatility, HSCS or MBAI?

Does the media refer more to HSCS or MBAI?

Summary

How does MBody AI compare to Femasys?

Which has more volatility & risk, FEMY or MBAI?

Which has higher earnings & valuation, FEMY or MBAI?

Do insiders & institutionals hold more shares of FEMY or MBAI?

Does the media prefer FEMY or MBAI?

Do analysts recommend FEMY or MBAI?

Is FEMY or MBAI more profitable?

Summary

How does MBody AI compare to SeaStar Medical?

Which has better earnings and valuation, MBAI or ICU?

Which has more risk and volatility, MBAI or ICU?

Is MBAI or ICU more profitable?

Do insiders and institutionals believe in MBAI or ICU?

Does the media favor MBAI or ICU?

Do analysts recommend MBAI or ICU?

Summary

How does MBody AI compare to IRIDEX?

Do institutionals and insiders believe in IRIX or MBAI?

Does the media refer more to IRIX or MBAI?

Do analysts rate IRIX or MBAI?

Which has stronger valuation and earnings, IRIX or MBAI?

Is IRIX or MBAI more profitable?

Which has more volatility and risk, IRIX or MBAI?

Summary

How does MBody AI compare to Cytosorbents?

Do institutionals & insiders hold more shares of MBAI or CTSO?

Do analysts recommend MBAI or CTSO?

Is MBAI or CTSO more profitable?

Which has more volatility and risk, MBAI or CTSO?

Does the media prefer MBAI or CTSO?

Which has higher valuation & earnings, MBAI or CTSO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBAI vs. The Competition

MBody AI Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools